The disposition of Captopril, an angiotensin‐converting enzyme inhibitor with
antihypertensive properties, was studied in 10 normal male subjects after a single 100‐mg …

Captopril, an angiotensin‐converting enzyme inhibitor with antihypertensive properties, was
given by mouth and intravenously in 10‐mg doses to five healthy subjects. After intravenous …

A sensitive assay is described for quantitating plasma captopril levels. Captopril is an orally
active inhibitor of angiotensin-con-verting enzyme. Blood from patients taking this drug was …

14C‐Captopril was administered as 100‐mg tablets to 12 subjects in a two‐way crossover
study in which subjects were either fasted or were given a standard meal immediately prior …

Blood concentration and urinary excretion of captopril following 50 mg oral administration
were determined by high-performance liquid chromatography in normal subjects and …

The pharmacokinetic properties of captopril were studied in two groups of hypertensive
patients:(1) those who had never taken captopril (acute group), and (2) those who had been …

Captopril, the first orally active inhibitor of angiotensin-converting enzyme, is used widely in
the treatment of hypertension and congestive heart failure. The pharmacokinetics of this …

A high-performance liquid chromatographic method has been developed which enables
sensitive determination of captopril and its mixed disulphides in plasma and urine after oral …

14C‐Captopril was given intravenously to four normal subjects in a 4‐mg priming dose
followed by constant intravenous infusion of 1.7 mg/hr for 3.5 hr with and without …

The kinetics of captopril plasma levels and of the drug‐induced plasma converting enzyme
activity (PCEA), plasma renin activity (PRA) and diastolic blood pressure (DBP) …